peterschreiber.media Oppenheimer started coverage of Dianthus Therapeutics ( NASDAQ: DNTH ) with an outperform rating, citing the market potential of its autoimmune therapy candidate DNTH103. The investment bank sees the market opportunity for the drug at nearly $20B, with a total addressable market for generalized myasthenia.